Short Interest in BriaCell Therapeutics Corp. (NASDAQ:BCTXW) Drops By 21.8%

BriaCell Therapeutics Corp. (NASDAQ:BCTXW) was the target of a large decrease in short interest during the month of January. As of January 15th, there was short interest totaling 4,166 shares, a decrease of 21.8% from the December 31st total of 5,328 shares. Based on an average daily volume of 173,275 shares, the short-interest ratio is currently 0.0 days. Based on an average daily volume of 173,275 shares, the short-interest ratio is currently 0.0 days.

BriaCell Therapeutics Stock Performance

NASDAQ:BCTXW traded down $0.00 during trading hours on Tuesday, reaching $0.01. The stock had a trading volume of 16,000 shares, compared to its average volume of 112,586. BriaCell Therapeutics has a 52 week low of $0.00 and a 52 week high of $0.25. The company has a 50 day moving average price of $0.04 and a two-hundred day moving average price of $0.04.

BriaCell Therapeutics Company Profile

BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on the development of novel immunotherapeutic treatments for breast cancer and other solid tumors. The company’s research strategy centers on harnessing the body’s immune system to recognize and attack cancer cells, with an emphasis on off-the-shelf allogeneic platforms that can be readily administered without the need for patient-specific manufacturing.

The company’s lead candidate, Bria-IMT, is derived from a human breast tumor cell line engineered to express immune-stimulatory molecules designed to trigger both innate and adaptive anti-tumor responses.